Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Squamous Cell Carcinoma Interventions:   Drug: Carrelizumab;   Drug: Paclitaxel injection;   Drug: Cisplatin;   Radiation: Concurrent chemoradiotherapy Sponsor:   The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials